Binding and inhibitory activities: A novel oral therapeutic agent for the treatment of hyperphosphataemia rats
Open Access
- 25 July 2022
- journal article
- research article
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 153, 113466
Abstract
No abstract availableKeywords
Funding Information
- Natural Science Foundation of Hebei Province (H2018201289)
- Hebei University
This publication has 28 references indexed in Scilit:
- VS‐501: a novel, nonabsorbed, calcium‐ and aluminum‐free, highly effective phosphate binder derived from natural plant polymerPharmacology Research & Perspectives, 2014
- Evaluation of the Relative Performance of 12 Urinary Biomarkers for Renal Safety Across 22 Rat Sensitivity and Specificity StudiesToxicological Sciences, 2013
- Serum phosphorus levels and pill burden are inversely associated with adherence in patients on hemodialysisNephrology Dialysis Transplantation, 2013
- Effects of Phosphate Binders in Moderate CKDJournal of the American Society of Nephrology, 2012
- Urine Biomarkers Predict Acute Kidney Injury in NewbornsThe Journal of Pediatrics, 2012
- Pill Burden, Adherence, Hyperphosphatemia, and Quality of Life in Maintenance Dialysis PatientsClinical Journal of the American Society of Nephrology, 2009
- Oral phosphate bindersKidney International, 2009
- Longitudinal Associations Between Dietary Protein Intake and Survival in Hemodialysis PatientsAmerican Journal of Kidney Diseases, 2006
- Consequences and management of hyperphosphatemia in patients with renal insufficiencyKidney International, 2005
- On the pathogenesis of hyperparathyroidism in chronic experimental renal insufficiency in the dogJournal of Clinical Investigation, 1971